Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1965 1
1966 5
1967 4
1968 3
1969 4
1970 3
1971 4
1972 2
1973 2
1974 1
1975 1
1976 1
1978 1
1979 1
1991 1
1992 2
1993 1
1994 3
1996 2
1999 3
2000 1
2002 1
2003 5
2004 3
2006 3
2007 7
2008 8
2009 8
2010 6
2011 7
2012 2
2013 3
2014 4
2015 6
2016 10
2017 3
2018 2
2019 5
2020 4
2021 5
2022 2
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Prenatal Diagnosis of 4q Terminal Deletion and Review of the Literature.
Tidrenczel Z, Tardy EP, Pikó H, Sarkadi E, Böjtös I, Demeter J, Simon J, Kósa JP, Beke A. Tidrenczel Z, et al. Among authors: kosa jp. Cytogenet Genome Res. 2019;158(2):63-73. doi: 10.1159/000500735. Epub 2019 Jul 2. Cytogenet Genome Res. 2019. PMID: 31261151 Review.
3D culturing of human pluripotent stem cells-derived endothelial cells for vascular regeneration.
Gara E, Zucchelli E, Nemes A, Jakus Z, Ajtay K, Kemecsei É, Kiszler G, Hegedűs N, Szigeti K, Földes I, Árvai K, Kósa J, Kolev K, Komorowicz E, Padmanabhan P, Maurovich-Horvat P, Dósa E, Várady G, Pólos M, Hartyánszky I, Harding SE, Merkely B, Máthé D, Szabó G, Radovits T, Földes G. Gara E, et al. Among authors: kosa j. Theranostics. 2022 Jun 6;12(10):4684-4702. doi: 10.7150/thno.69938. eCollection 2022. Theranostics. 2022. PMID: 35832092 Free PMC article.
[Literature review and presentation of our own research results regarding the effects on bone of tyrosine kinase inhibitors imatinib and nilotinib used in the treatment of oncohematological diseases].
Kirschner G, Balla B, Kósa J, Horváth P, Kövesdi A, Lakatos G, Takács I, Nagy Z, Tóbiás B, Árvai K, Lakatos P. Kirschner G, et al. Among authors: kosa j. Orv Hetil. 2016 Sep;157(36):1429-37. doi: 10.1556/650.2016.30525. Orv Hetil. 2016. PMID: 27596510 Review. Hungarian.
[Childhood accidents].
Kazár G, Ihász M, Kósa J, Pestessy J. Kazár G, et al. Among authors: kosa j. Orv Hetil. 1992 Aug 2;133(31):1937-43. Orv Hetil. 1992. PMID: 1495803 Review. Hungarian.
Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.
Tobiás B, Halászlaki C, Balla B, Kósa JP, Árvai K, Horváth P, Takács I, Nagy Z, Horváth E, Horányi J, Járay B, Székely E, Székely T, Győri G, Putz Z, Dank M, Valkusz Z, Vasas B, Iványi B, Lakatos P. Tobiás B, et al. Among authors: kosa jp. Pathol Oncol Res. 2016 Jan;22(1):27-33. doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11. Pathol Oncol Res. 2016. PMID: 26259532 Free article.
SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw.
Yang G, Collins JM, Rafiee R, Singh S, Langaee T, McDonough CW, Holliday LS, Wang D, Lamba JK, Kim YS, Pelliccioni GA, Vaszilko M, Kosa JP, Balla B, Lakatos PA, Katz J, Moreb J, Gong Y. Yang G, et al. Among authors: kosa jp. J Bone Miner Res. 2021 Feb;36(2):347-356. doi: 10.1002/jbmr.4185. Epub 2020 Oct 23. J Bone Miner Res. 2021. PMID: 32967053 Free PMC article.
130 results